Nesto, R.W., Bell, D., Bonow, R.O., Fonseca, V., Grundy, S.M., Horton, E.S., et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Asso-ciation and American Diabetes Association. Circulation, 108, 2941-2948.

has been cited by the following article:

• TITLE: Pioglitazone does not modify ANP levels of type 2 diabetic patients

  AUTHORS: Stefano Benedini, Paolo Villa, Livio Luzi, Maurizio Bevilacqua

  KEYWORDS: Atrial Natriuretic Peptide; Pioglitazone; Insulin Resistance; Blood Glucose

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.2 No.4, October 30, 2012

  ABSTRACT: Background: The atrial natriuretic peptide (ANP) regulates fluid volume redistribution between heart and the pulmonary vessels. In diabetic patients the physiological action of ANP appears to be seriously altered. Methods: 12 subjects (gender 6M/6F, age 47 ± 2 years, BMI 29.1 ± 0.1 kg/m2), with type 2 diabetes and under stable conditions, were studied after one month of pioglitazione treatment (30 mg/die) by means of isotonic blood volume expansion. Results: After one month of pioglitazone treatment the meta- bolic profile of the subjects improved (decrease dia- stolic blood pressure: p = 0.05, total cholesterol: p = 0.01, triglycerides: p = 0.03 and blood glucose: p = 0.01) as the expansion of their plasma volume was found associated with the decrease of hematocrit (p